JP2011506334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506334A5 JP2011506334A5 JP2010537045A JP2010537045A JP2011506334A5 JP 2011506334 A5 JP2011506334 A5 JP 2011506334A5 JP 2010537045 A JP2010537045 A JP 2010537045A JP 2010537045 A JP2010537045 A JP 2010537045A JP 2011506334 A5 JP2011506334 A5 JP 2011506334A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- antigen
- microparticles
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 114
- 230000002163 immunogen Effects 0.000 claims description 97
- 239000000427 antigen Substances 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 239000011859 microparticle Substances 0.000 claims description 58
- 239000002671 adjuvant Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 229920002988 biodegradable polymer Polymers 0.000 claims description 13
- 239000004621 biodegradable polymer Substances 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 201000005702 Pertussis Diseases 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims description 7
- 229940124669 imidazoquinoline Drugs 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 241000588650 Neisseria meningitidis Species 0.000 claims description 5
- 239000003945 anionic surfactant Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 201000006082 Chickenpox Diseases 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 201000005505 Measles Diseases 0.000 claims description 4
- 206010034038 Parotitis Diseases 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 206010046980 Varicella Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 206010013023 diphtheria Diseases 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 201000005404 rubella Diseases 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 239000007762 w/o emulsion Substances 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229940065514 poly(lactide) Drugs 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 238000000935 solvent evaporation Methods 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US570407P | 2007-12-07 | 2007-12-07 | |
| PCT/US2008/085506 WO2009076158A1 (en) | 2007-12-07 | 2008-12-04 | Compositions for inducing immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014117206A Division JP6013400B2 (ja) | 2007-12-07 | 2014-06-06 | 免疫応答を誘導するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506334A JP2011506334A (ja) | 2011-03-03 |
| JP2011506334A5 true JP2011506334A5 (https=) | 2012-02-02 |
Family
ID=40329118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537045A Pending JP2011506334A (ja) | 2007-12-07 | 2008-12-04 | 免疫応答を誘導するための組成物 |
| JP2014117206A Expired - Fee Related JP6013400B2 (ja) | 2007-12-07 | 2014-06-06 | 免疫応答を誘導するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014117206A Expired - Fee Related JP6013400B2 (ja) | 2007-12-07 | 2014-06-06 | 免疫応答を誘導するための組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8815253B2 (https=) |
| EP (2) | EP3067048B1 (https=) |
| JP (2) | JP2011506334A (https=) |
| AU (1) | AU2008335457B2 (https=) |
| CA (1) | CA2708145C (https=) |
| ES (1) | ES2664753T3 (https=) |
| WO (1) | WO2009076158A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2762653A1 (en) * | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| ES2536429T3 (es) * | 2010-01-24 | 2015-05-25 | Novartis Ag | Micropartículas de polímero biodegradables irradiadas |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| CA2830948A1 (en) * | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| US9358461B2 (en) | 2012-12-26 | 2016-06-07 | Sony Interactive Entertainment America Llc | Systems and methods for ranking of cloud executed mini-games based on tag content and social network content |
| WO2015053354A1 (ja) * | 2013-10-09 | 2015-04-16 | 東レ株式会社 | 免疫賦活化剤 |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2800457A (en) | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
| NL134977C (https=) | 1962-07-11 | |||
| EP0142193A1 (en) | 1983-10-22 | 1985-05-22 | Akzo N.V. | Preparation of immunogens consisting of antigens and/or antigenic determinants bound to glycoside-containing carriers |
| US5324513A (en) | 1984-03-07 | 1994-06-28 | Institut Pasteur | Composition useful for the fabrication of vaccines |
| US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US5098704A (en) | 1984-06-18 | 1992-03-24 | Chiron Corporation | Hepatitis surface antigen particle vaccine |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US4727136A (en) | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
| ES2061500T5 (es) | 1986-06-17 | 2003-05-16 | Chiron Corp | Diagnosis y vacunas de la hepatitis delta, su preparacion y uso. |
| NZ227011A (en) | 1987-11-18 | 1992-03-26 | Chiron Corp | Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits |
| US5350671A (en) | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| KR0185373B1 (ko) | 1989-03-17 | 1999-05-01 | 로버트 피. 블랙버언 | Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용 |
| DK0398748T3 (da) | 1989-05-18 | 2002-03-18 | Chiron Corp | NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69019164T2 (de) | 1989-12-14 | 1995-09-07 | National Research Council Of Canada, Ottawa, Ontario | Verbessertes meningokokkale polysaccharidkonjugatvakzin. |
| US5614612A (en) | 1990-03-09 | 1997-03-25 | Haigwood; Nancy L. | Purified gp120 compositions retaining natural conformation |
| US6274148B1 (en) | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| WO1993000365A2 (en) | 1991-06-24 | 1993-01-07 | Chiron Corporation | Hepatitis c virus (hcv) polypeptides |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| UA39944C2 (uk) | 1992-07-07 | 2001-07-16 | Чірон Корпорейшн | Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| ES2182850T3 (es) * | 1993-10-22 | 2003-03-16 | Genentech Inc | Procedimientos y composiciones para la microencapsulacion de adyuvantes. |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| AU3241095A (en) | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9422096D0 (en) | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US5843752A (en) | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
| US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
| CA2250723C (en) | 1996-05-24 | 2012-07-17 | Chiron Corporation | Multiple epitope fusion protein |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| PT991403E (pt) | 1997-01-30 | 2003-08-29 | Chiron Corp | Uso de microparticulas com antigenio adsorvido para estimular respostas imunes |
| DK0969862T3 (da) | 1997-02-07 | 2007-02-12 | Merck & Co Inc | Syntetisk HIV gag-gener |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP0980257A1 (en) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| CA2288374A1 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| CA2301942C (en) | 1997-08-27 | 2011-05-31 | Chiron Corporation | Molecular mimetics of meningococcal b epitopes |
| ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| IL135480A0 (en) | 1997-10-31 | 2001-05-20 | Cistron Biotechnology Inc | Encapsulated immunomodulators useful as vaccine adjuvants |
| CN1263854C (zh) | 1997-11-06 | 2006-07-12 | 启龙股份公司 | 奈瑟球菌抗原 |
| ES2175668T3 (es) * | 1997-12-16 | 2002-11-16 | Chiron Corp | Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas. |
| AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
| EP2261352A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| AU763975B2 (en) | 1998-07-29 | 2003-08-07 | Novartis Vaccines And Diagnostics, Inc. | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| BR9914374A (pt) | 1998-10-09 | 2002-09-17 | Chiron Corp | Sequências genÈmicas de neisseria e métodos para seu uso |
| WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| ES2223464T3 (es) | 1999-02-01 | 2005-03-01 | Eisai Co., Ltd. | Compuestos adyuvantes inmunologicos. |
| US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| ES2275499T3 (es) | 1999-03-19 | 2007-06-16 | Glaxosmithkline Biologicals S.A. | Vacuna contra streptococcus pneumoniae. |
| DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| KR20020048942A (ko) | 1999-09-24 | 2002-06-24 | 장 스테판느 | 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트 |
| CZ20021043A3 (cs) | 1999-09-24 | 2002-08-14 | Smithkline Beecham Biologicals S. A. | Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku |
| DE60043708D1 (de) * | 1999-10-13 | 2010-03-04 | Novartis Vaccines & Diagnostic | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| EP2241309A3 (en) * | 2001-07-10 | 2012-12-26 | Corixa Corporation | Methods for encapsulation of proteins and adjuants in microspheres |
| CN100354297C (zh) | 2001-10-03 | 2007-12-12 | 希龙公司 | 辅助的脑膜炎球菌组合物 |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| JP2005519990A (ja) * | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
| EP1465659A4 (en) | 2001-12-21 | 2005-09-14 | Children S Hospital And Region | USING A NEW CELL SURFACE PROTEASE FROM STREPTOCOCCUS GROUP B |
| EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
| GB0206461D0 (en) | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
| DK1487485T3 (da) * | 2002-03-19 | 2011-03-14 | Powderject Res Ltd | Imidazoquinolinadjuvanser til DNA-vacciner |
| CA2511646A1 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| AU2003299994A1 (en) * | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
| US7731967B2 (en) * | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| EP1631264B8 (en) * | 2003-06-02 | 2017-05-24 | GlaxoSmithKline Biologicals SA | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| DE102004032952A1 (de) * | 2004-07-07 | 2006-01-26 | Leica Microsystems Cms Gmbh | Rastermikroskop und Verfahren zur Untersuchung von biologischen Proben mit einem Rastermikroskop |
| US20080213308A1 (en) * | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
| ES2434029T3 (es) | 2004-11-15 | 2013-12-13 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido |
| NZ568211A (en) * | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| WO2007100699A2 (en) * | 2006-02-24 | 2007-09-07 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
| WO2007109810A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
-
2008
- 2008-12-04 EP EP16164271.5A patent/EP3067048B1/en active Active
- 2008-12-04 US US12/746,723 patent/US8815253B2/en active Active
- 2008-12-04 JP JP2010537045A patent/JP2011506334A/ja active Pending
- 2008-12-04 WO PCT/US2008/085506 patent/WO2009076158A1/en not_active Ceased
- 2008-12-04 AU AU2008335457A patent/AU2008335457B2/en not_active Ceased
- 2008-12-04 ES ES16164271.5T patent/ES2664753T3/es active Active
- 2008-12-04 EP EP08860518A patent/EP2244695A1/en not_active Withdrawn
- 2008-12-07 CA CA2708145A patent/CA2708145C/en not_active Expired - Fee Related
-
2014
- 2014-06-06 JP JP2014117206A patent/JP6013400B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506334A5 (https=) | ||
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| O’Hagan et al. | New generation adjuvants–from empiricism to rational design | |
| Azmi et al. | Recent progress in adjuvant discovery for peptide-based subunit vaccines | |
| Rosenthal et al. | Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale | |
| Wang et al. | Selection of adjuvants for enhanced vaccine potency | |
| CA2528007A1 (en) | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen | |
| Leroux-Roels | Unmet needs in modern vaccinology: adjuvants to improve the immune response | |
| Genito et al. | Considerations for size, surface charge, polymer degradation, co‐delivery, and manufacturability in the development of polymeric particle vaccines for infectious diseases | |
| JP2006526649A5 (https=) | ||
| Kocourkova et al. | Vaccine ingredients: components that influence vaccine efficacy | |
| Strugnell et al. | Vaccine antigens | |
| Kallerup et al. | Classification of vaccines | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| JP5867952B2 (ja) | ベンゾナフチリジン含有ワクチン | |
| JP2014521687A5 (https=) | ||
| JP6013400B2 (ja) | 免疫応答を誘導するための組成物 | |
| Singh et al. | Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems | |
| Bramwell et al. | Particulate delivery systems for vaccines: what can we expect? | |
| KR20200040812A (ko) | 폐렴구균 접합체 백신 제제 | |
| Nguyen et al. | Skin immunization with third-generation hepatitis B surface antigen using microneedles | |
| JP2017014217A5 (https=) | ||
| Dey et al. | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens | |
| JP2017507165A5 (https=) | ||
| JP2018534304A5 (https=) |